Coronary artery disease (CAD), Hypertension (Ht) and Type 2 Diabetes Mellitus (T2DM) are all global health problems. This is particularly evident amongst South Asian population groups. The conventional risk factors do not fully explain the higher prevalence of these diseases among South Asians. The endothelial Nitric Oxide Synthase (eNOS) gene is responsible for the production of Nitric Oxide (NO), which may contribute to the physiology of all three disease states. Endothelial dysfunction (which is characterised by a reduction in basal NO) has been shown to be present in, or prior to all three diseases. Numerous variations exist within the eNOS gene, of these variations three have been shown to have a possible functional effect. The first is the Glu298Asp polymorphism within the exon region of the gene, resulting in an amino acid substitution of Glutamate (Glu) to Aspartate (Asp). The second, known as the T-786C polymorphism, is a thymine to cytosine mutation at position -786 in the promoter region. Finally a VNTR polymorphism in Intron 4 causes either a 4 27bp repeat or a 5 27bp repeat. It is hypothesised that these variations could have an effect on the ability of eNOS to produce NO and thus may increase the risk or contribute to the development of the diseases. Previous studies on these variants have shown conflicting results and further studies are warranted to understand and confirm the role of eNOS gene polymorphisms in cardio-metabolic diseases. There is very limited research into the distributions of these genetic variants and their interaction in diseases processes in North Indian populations. Objectives: 1. To analyse through a case control study three different polymorphisms of the eNOS gene for possible association with Coronary Artery Disease (CAD), Hypertension (Ht) and Type 2 Diabetes Mellitus (T2DM) in North Indian population groups. 2. To statistically evaluate descriptive statistics including; age, gender, smoking, dietary behaviours and lipid parameters for possible influence on disease and potential interaction with genetic polymorphisms. 3. To evaluate linkage disequilibrium between the three eNOS variants and carryout haplotype analysis to work out haplotype risk in different diseases. 4. To analyse through a case control study the deletion variant of the Angiotensin-converting enzyme (ACE) gene for possible association with Coronary Artery Disease (CAD), Hypertension (Ht) and Type 2 Diabetes Mellitus (T2DM) in North Indian population groups. 5. To determine a possible interactive effect of the eNOS polymorphisms with the ACE polymorphism. Subjects and Methods: The Glu298Asp and Intron 4 variants were genotyped using a PCR-RFLP technique, the T-786C variant was genotyped using a real time-PCR technique. The ACE deletion variant was also genotyped using a standard PCR technique. The genotyping was undertaken in a total of 457 CAD patients and 220 matched controls from Lucknow, Uttar Pradesh in North India, 319 T2DM patients and 307 matched controls from Punjab, North India and 210 Ht and 162 matched controls, also from Punjab, North India. Results: CAD: The Glu298Asp was significantly associated with CAD among smokers (TT+GT vs. GG OR=2.84 (CI: 1.61-5.0), p<0.001). The Intron 4 variant was also significantly associated with CAD in a smoking dependent manner (4aa+4ab vs. 4bb OR=0.56 (CI: 0.33-0.96). The T-786C variant showed no overall influence on CAD risk. There was also evidence for both synergistic and haplotypic effects of the eNOS gene on CAD status (haplotype G-C-4b OR=4.76 (CI: 1.43-15.78), p<0.001). The ACE genetic variant was confirmed to be a strong independent risk factor for CAD under a dominant model (OR=2.18 (CI: 1.46-3.25), p<0.001). There was no evidence for an interactive effect between the ACE deletion and any of the three eNOS variants incorporated in the current study. Ht: The Glu298Asp variant was not shown to increase Ht risk, with a reduced risk association found under a recessive model (OR=0.316 (CI:0.089-1.116)), p=0.061). The T-786C variant s role in disease remained unclear with the findings showing a non significant increased risk. The Intron 4 variant was also shown to increase Ht risk, in a non significant manner. Sufficiently powered studies would be required to clarify these possible associations. The combined analysis, using logistic regression and haplotype analysis revealed no significant associations, but there was a possible protective effect of the T-C-4b haplotype (OR=0.46 (CI: 0.21-1.01), p=0.054). The ACE gene variant was confirmed to be a strong independent risk factor for Ht under a recessive model (OR=1.81 (CI: 1.20-2.74), p=0.01). Again there was no evidence for an interactive effect between the ACE deletion and any of the three eNOS variants in hypertension. T2DM: The Glu298Asp variant was found to be associated with T2DM under a dominant model, the protective effect remained significant following adjustment for conventional risk factors and other gene variants (OR=0.407 (CI: 0.231-0.717), p=0.002). The T-786C variant showed no overall influence on T2DM risk. The Intron 4 variant also found no overall influence. Haplotype analysis found the T-T-4b was found to be significantly protective for T2DM (OR=0.41 (CI: 0.26-0.65), p=0.0002). Finally the ACE gene variant was confirmed to be a risk factor for T2DM under a dominant model (OR=2.62 (CI: 1.51-4.54), p=0.001). Overall Conclusions: To conclude, this study successfully identified the frequency of three eNOS gene variants and the ACE deletion variant in three complex diseases within north Indian populations. There is a clear role of the eNOS gene in all three diseases and consequently the genetic variants have susceptible/protective associations. The association with disease was found to be present at an individual level, in association with risk factors and at a haplotypic level. These findings warrant further studies to confirm and untangle the genetics of complex diseases and genetic risk profiles calculations which will contribute to the field of medical genomics/personalised medicare and interventions among North Indian populations.

INTRODUÇÃO: A importância da resposta mecânica do parênquima pulmonar na fisiopatologia da asma tem sido recentemente reconhecida. O óxido nítrico é um mediador que controla o tônus muscular liso das vias aéreas, porém este efeito no parênquima pulmonar periférico ainda não foi previamente investigado. Nossa hipótese é que a inibição crônica das óxido nítrico sintases por meio do tratamento com L-NAME (falso substrato para todas as óxido nítrico sintases) pode modular a mecânica do parênquima pulmonar, o recrutamento eosinofílico e o remodelamento da matriz extracelular em modelo de inflamação alérgica crônica pulmonar em cobaias. MÉTODOS: Os animais foram expostos a sete inalações com soro fisiológico ou com ovoalbumina em doses crescentes (1~5mg/ml - 4 semanas) e tratadas ou não com L-NAME (60 mg/kg/ por dia /por animal) na água de beber. Setenta e duas horas após a sétima inalação os animais foram anestesiados, exsanguinados e a mecânica oscilatória do parênquima pulmonar foi medida na condição pré e após desafio (0.1%). Utilizando a técnica de morfometria foram avaliadas a densidade de eosinófilos, o número de células nNOS e iNOS positivas, a densidade de actina, das fibras colágenas e das fibras elásticas bem como a proporção de volume de 8-iso-PGF2 no septo alveolar. RESULTADOS: Os animais que foram expostos à ovoalbumina apresentaram um aumento da resistência e da elastância tecidual (resposta basal e após desafio antigênico), na densidade de eosinófilos, no número de células nNOS e iNOS positivas, na densidade de fibras colágenas e de fibras elásticas bem como na expressão de 8-isoPGF2 no septo alveolar comparativamente aos grupos controles (p<0,05). O tratamento com L-NAME em animais expostos à ovoalbumina atenuou todas as respostas de mecânica do tecido pulmonar periférico (p<0, 01), reduziu o número de células nNOS e iNOS positivas (p<0.01), o conteúdo de fibras elásticas (p<0,001) e de 8-iso-PGF2 no septo alveolar (p<0,001). No entanto, este tratamento não afetou o número total de eosinófilos e o conteúdo de fibras colágenas. Este trabalho sugere que o óxido nítrico contribui para a constrição do parênquima pulmonar e para a deposição de fibras elásticas neste modelo. Estes efeitos foram associados à ativação de iNOS e nNOS em células do parênquima distal e aumento na via do estresse oxidativo / The importance of lung tissue mechanical responses in asthma pathophysiology has been recently recognized. Although nitric oxide (NO) is a mediator that controls smooth muscle tonus control in the airways, its effects on lung tissue responsiveness has not been previously investigated. We hypothesized that chronic nitric oxide synthase inhibition by L-NAME (false substrate for all nitric oxide synthases) treatment may modulate lung tissue mechanics, eosinophilic recruitment and extracellular matrix remodeling in a model of chronic pulmonary allergic inflammation. Guinea pigs were submitted to seven normal saline or ovalbumin exposures with increasing doses (1~5mg/mL-4weeks) and treated or not with L-NAME in drinking water. Seventy-two hours after the seventh inhalation the animals were anesthetized, exsanguinated, and oscillatory mechanics of lung tissue strips was performed in baseline condition and after ovalbumin challenge (0.1%). Using morphometry, we assessed the density of eosinophils, the number of iNOS and nNOS-positive cells, the density of actin, the collagen and elastic fibers content and the volume proportion of 8-iso-PGF2 in the alveolar septa. Ovalbumin-exposed animals presented an increase in baseline and maximal tissue resistance and elastance responses, eosinophil density, in the number of iNOS and nNOS positive cells, in the amount of collagen and elastic fibers and in the volume proportion of 8-iso-PGF2 in the alveolar septa compared to controls (p<0.05). L-NAME treatment in ovalbumin-exposed animals attenuated all lung tissue mechanical responses (p<0.01), reduced the number of iNOS and nNOS positive cells (p<0.01), elastic fiber content (p<0.001) and 8-isoPGF2 in the alveolar septa (p<0.001). However, this treatment did not affect the total number of eosinophils and collagen deposition. These data suggest that NO contributes to distal lung parenchyma constriction and to elastic fibers deposition in this model. These effects were associated to iNOS and nNOS activation in pulmonary parenchyma and with an increase in oxidative stress pathway activation

Na busca por novos materiais doadores de óxido nítrico (NO), o presente trabalho descreve o desenvolvimento de um filme à base de amido de mandioca, no qual foi incorporado um nitrosilo complexo de rutênio, e o estudo da liberação de NO nesse material. O nitrosilo complexo trans-[Ru(NH3)4(isn)NO](BF4)3 (RuNOisn; isn = isonicotinamida) apresenta a propriedade de liberar NO de forma controlada, por meio de fotólise (&lambda;irr = 310-370 nm) e de redução química. A incorporação desse complexo em filmes de amido foi realizada em condições brandas, resultando em um novo material para o armazenamento e liberação de NO, designado como CSx-RuNOisn. Os ensaios espectroscópicos indicaram que a esfera de coordenação do complexo RuNOisn permaneceu inalterada durante a produção dos filmes. A exposição de CSx-RuNOisn à luz (&lambda;irr = 355 nm) levou à liberação de NO e provavelmente à formação do fotoproduto trans [RuIII(NH3)4isn(H2O)]3+ no filme. A reação desse aquocomplexo de rutênio(III) com solução aquosa contendo nitrito de sódio regenerou o complexo de partida, RuNOisn. A identificação e quantificação do NO liberado durante a fotólise foi efetuada por meio da reação com oximioglobina. Durante o tempo de irradiação de 17 minutos, foram liberados 5,02 &plusmn; 0,12 &mu;M de NO (10, 04 &plusmn; 0,24 nmol NO em 2 mL). Os ensaios de liberação de NO desencadeada por redução foram realizados utilizando-se L-cisteína como redutor. O fluxo de NO liberado a partir da reação com cisteína perdurou por mais de 7 horas, alcançando-se concentrações fisiologicamente relevantes, com fluxo médio de 1,9 pmol NO s-1 cm-2 de filme. Esse valor é comparável àquele produzido por células endoteliais, em que o fluxo de NO é de 1,67 pmol s-1 cm-2. Os resultados preliminares de degradação dos filmes in vivo sugerem que o material foi degradado pelo organismo em 30 dias. Todos os resultados alcançados sugerem que o filme CSx-RuNOisn é um candidato promissor para aplicações em meio biológico. Um novo complexo de rutênio contendo o ligante nitrosilsulfito (N(O)SO3 -) foi isolado, trans [Ru(NH3)4(isn)(N(O)SO3)](X) (isn = isonicotinamida, X = PF6- ou SiPF6 2-), e a sua estrutura cristalina determinada por difração de raio-X. A síntese desse complexo foi realizada por meio da reação entre trans-[Ru(NH3)4(isn)(NO)]3+ e íons sulfito (SO32-). O ataque nucleofílico do SO32- ocorreu no nitrogênio do ligante nitrosônio (NO) coordenado ao centro metálico de rutênio ([Ru-NO+]), originando o ligante O=N-SO3-: [RuNO+]3+ + SO32- &rarr;[Ru(N(O)SO3)]+. Observou-se que em meio aquoso, no intervalo de pH de 7,4 a 5,2 o complexo trans [Ru(NH3)4(isn)(N(O)SO3)]+ é estável, e a velocidade de decomposição (labilização do ligante isn) variou de k = 0,86 a 3,07 × 10-5 s-1. Em soluções mais ácidas (tampão ácido acético/acetato pH 4,2, 3,9, ou 1,0 M ácido trifluoroacético) o complexo trans-[Ru(NH3)4(isn)(N(O)SO3)]+ decompõe-se formando o respectivo nitrosilo complexo trans- [RuII(NH3)4(isn)NO+]3+. A reação do íon trans-[Ru(NH3)4(isn)(N(O)SO3)]+ com íons hidróxido (OH-) dá origem ao respectivo nitro complexo trans-[Ru(NH3)4(isn)(NO2)]+, que foi caracterizado por RMN de 15N e por espectroscopia eletrônica. As constantes de velocidade para essa reação são k = 6,16 &plusmn; 0,22 M-1 s-1 à T = 25oC, e k = 2,15 &plusmn; 0,07 M-1 s-1 à T = 15oC. A reação entre o nitrosilo complexo trans [RuII(NH3)4(isn)NO+]3+ e íons OH- também resulta na formação do nitro complexo trans-[Ru(NH3)4(isn)(NO2)]+. Neste caso, a constante de velocidade foi estimada entre k = 47-58 M-1 s-1 à T = 25oC, e o valor obtido experimentalmente à T = 15oC foi de k = 10,53 &plusmn; 0,29 M-1 s-1. O espectro eletrônico do íon complexo trans [Ru(NH3)4(isn)(N(O)SO3)]+ em meio aquoso apresentou uma banda larga com &lambda; max = 362 nm (&epsilon; &sim;6000 M-1 cm-1), atribuída por cálculos teóricos às seguintes transições: transferência de carga do metal para o ligante (TCML) Ru &rarr; N(O)SO3 e Ru &rarr; isn, e também d &rarr; d. Os ensaios preliminares de fotólise (&lambda; irrad = 355 nm) do complexo trans[Ru(NH3)4(isn)(N(O)SO3)](PF6) em solução de tampão fosfato (pH 7,4) sugerem a formação das seguintes espécies nos intervalos iniciais de fotólise: i) NO, ii) SO3 &bull;-, e iii) isn (labilizado do complexo). O mecanismo para a formação desses produtos ainda está sob investigação. / Aiming the production of new nitric oxide releasing materials (NORM), this work reports the development of a cassava starch based film, in which a ruthenium nitrosyl complex was impregnated, and evaluate the NO release from this film. Ruthenium nitrosyl complex trans-[Ru(NH3)4(isn)NO](BF4)3 (RuNOisn; isn = isonicotinamide) is able to release NO in a controlled manner through both photolysis (&lambda;irr = 310-370 nm) and chemical reduction. The incorporation of such complex into the starch-based films was performed under mild conditions, yielding a new material able to store and release NO, abbreviated as CSx-RuNOisn. Spectroscopic analysis of CSx-RuNOisn indicated that the coordination sphere of RuNOisn remained intact during film production. Exposure of CSx-RuNOisn to long wave UV-light (&lambda;irr = 355 nm) leads to NO release and likely to the formation of the paramagnetic photoproduct trans-[RuIII(NH3)4isn(H2O)]3+ in the film. Reaction of this aquoruthenium(III) complex with aqueous nitrite regenerates RuNOisn in the film. Delivery of NO upon photolysis of CSx-RuNO isn was verified and quantified by trapping with oxymyoglobin. The calculated concentration of NO released from the film was 5.02 &plusmn; 0.12 &mu;M (10.04 &plusmn; 0.24 nmol NO in a 2 mL) after approximately 17 min of irradiation (500 laser pulses at 2 s intervals). Moreover, NO release upon chemical reduction was carried out using L-cysteine as a reductant. Cysteine-mediated NO delivery from CSx-RuNOisn persisted for more than 7 h, during which physiologically relevant NO concentrations were liberated (average flux of 1.9 pmol NO s-1 cm-2 of film). This value is comparable to that produced by endothelial cells (1.67 pmol s-1 cm-2). Preliminary results about the biodegradation of the films in vivo suggest that the films were completely absorbed by the organism in a period of 30 days. These results suggest that CSx-RuNOisn is a promising candidate for use in biological applications. A new nitrosylsulphito complex bearing the ligand (N(O)SO3-) was isolated, trans-[Ru(NH3)4(isn)(N(O)SO3)](X) (isn = isonicotinamide, X = PF6- or SiPF6-), and its structure was determined by X-Ray crystallography. This complex was obtained by the reaction between trans-[Ru(NH3)4(isn)(NO)]3+ and sulfite ions (SO32-). X-Ray results confirmed that the nucleophilic attack of the sulphite anion (SO32-) was on the nitrogen atom of the nitrosyl ligand (NO) coordinated to the ruthenium center ([Ru-NO+]), yielding the ligand O=N-SO3-: [RuNO+]3+ + SO32- &rarr; [Ru(N(O)SO3)]+. Complex trans- [Ru(NH3)4(isn)(N(O)SO3)]+ is stable in aqueous solution from pH 7.4 to 5.2, and the decomposition rates (k) (due to the isn labilization) are in the range of k = 0.86-3.07 × 10-5 s-1. In more acidic conditions, (acetate buffer pH 4.2, 3.9, and trifluoroacetic acid solution 1.0 M) complex trans-[Ru(NH3)4(isn)(N(O)SO3)]+ is converted into the respective nitrosyl trans-[RuII(NH3)4(isn)NO+]3+. Reaction of trans-[Ru(NH3)4(isn)(N(O)SO3)]+ and hydroxide ions (OH-) yielded the nitro complex trans-[Ru(NH3)4(isn)(NO2)]+, which was characterized by 15N NMR and electronic spectroscopy. Rate constants for such reaction are k = 6.16 &plusmn; 0.22 M-1 s-1 at 25oC, and k = 2.15 &plusmn; 0.07 M-1 s-1 at 15oC. In the case of complex trans-[RuII(NH3)4(isn)NO+]3+, its reaction with OH- also yield the nitro complex trans-[Ru(NH3)4(isn)(NO2)]+. The estimated rate constant for such reaction was k = 46.9-57.6 M-1 s-1 at 25oC, and the experimental value obtained at 15oC was k = 10.53 &plusmn; 0.29 M-1 s-1. The ion complex trans-[Ru(NH3)4(isn)(N(O)SO3)]+ showed an intense and broad band at 362 nm (&epsilon;&sim;6000 M-1 cm-1) in aqueous solutions, which was assigned by DFT calculations to the following transitions: metal to ligand charge transfer (MLCT) Ru&rarr;N(O)SO3 and Ru&rarr;isn, and d&rarr;d as well. Preliminary photolysis assays (&lambda;irrad = 355 nm) performed with complex trans-[Ru(NH3)4(isn)(N(O)SO3)](PF6) in phosphate buffer solution (pH 7,4) suggests that the following species have been formed (in the initial photolysis period): i) NO, ii) SO3&bull;-, and iii) isn (labilized). The whole mechanism to yield such products is still under investigation.

O objetivo deste estudo foi avaliar o efeito da sinvastatina, isolada e associada ao &#945;-tocoferol e à L-arginina, sobre os inibidores endógenos da óxido nítrico sintase, os metabólitos do óxido nítrico e tióis, em pacientes hipercolesterolêmicos. Analisou-se um grupo de 16 pacientes hipercolesterolêmicos que seguiram o seguinte protocolo: período de washout (sem medicação), 1 mês; sinvastatina (20mg/dia), 2 meses; sinvastatina (20mg/dia) + &#945;-tocoferol (400U/dia), 2 meses; sinvastatina (20mg/dia, washout), 1 mês; sinvastatina (20mg/dia) + L-arginina (7g/dia), 2 meses. A sinvastatina reduziu significativamente as concentrações do colesterol total e LDL-colesterol e a razão LDL-colesterol/HDL-colesterol. O tratamento com sinvastatina, isolada e associada ao &#945;-tocoferol, promoveu diminuição nas concentrações de S-nitrosotióis. A L-arginina associada à sinvastatina, aumentou os níveis de colesterol total quando comparada com a sinvastatina isoladamente. As concentrações plasmáticas de &#945;-tocoferol e L-arginina não aumentaram em decorrência da suplementação, devido à grande dispersão dos dados obtidos, embora as medianas das concentrações plasmáticas de Larginina e &#945;-tocoferol tenham sido mais elevadas após as suplementações. O tratamento com sinvastatina, isolada ou associada à L-arginina e ao &#945;-tocoferol, não alterou as concentrações dos inibidores endógenos da óxido nítrico sintase (ADMA e SDMA), dos metabólitos do óxido nítrico, da nitrotirosina total e dos tióis analisados. / The aim of this study was to evaluate the effect of sinvastatin, isolated and associated to &#945;-tocopherol and to L-arginine, on the endogenous inhibitors of nitric oxide synthase, on nitric oxide metabolytes and thiols, in hypercholesterolemic patients. A group of 16 hypercholesterolemic patients were analysed, acconting to the protocol: a washout period (without medication) of 1 month, sinvastatin (20 mg/day) for 2 months; sinvastatin (20 mg/day) + &#945;-tocopherol (400U/day) for 2 months; sinvastatin (20 mg/day) for 1 months (washout period), sinvastatin (20 mg/day) + L-arginine (7g/day) for 2 months. Sinvastatin significantly reduced the concentrations of total cholesterol and LDL-cholesterol, as well as the LDL-cholesterol/HDLcholesterol ratio. The treatment with sinvastatina, alone and associate to &#945;-tocoferol, resulted in a reduction of RSNO concentration. The L-arginine associated with sinvastatin, increase the level of total cholesterol as compared with simvastatin alone. The plasma concentrations of a-tocopherol and Larginine did not increase following supplementation due to the large dispersion of the data obtained, even though the median plasma concentrations of L-arginine and a-tocopherol were elevated after supplementation. Treatment with simvastatin, alone or associated to L-arginine and a-tocopherol did not alter the concentrations of the endogenous inhibitors of nitric oxide synthase (ADMA and SDMA), or that of nitric oxide metabolytes, total nitrotyrosine or the thiols analysed.

Na busca por novos materiais doadores de óxido nítrico (NO), o presente trabalho descreve o desenvolvimento de um filme à base de amido de mandioca, no qual foi incorporado um nitrosilo complexo de rutênio, e o estudo da liberação de NO nesse material. O nitrosilo complexo trans-[Ru(NH3)4(isn)NO](BF4)3 (RuNOisn; isn = isonicotinamida) apresenta a propriedade de liberar NO de forma controlada, por meio de fotólise (&lambda;irr = 310-370 nm) e de redução química. A incorporação desse complexo em filmes de amido foi realizada em condições brandas, resultando em um novo material para o armazenamento e liberação de NO, designado como CSx-RuNOisn. Os ensaios espectroscópicos indicaram que a esfera de coordenação do complexo RuNOisn permaneceu inalterada durante a produção dos filmes. A exposição de CSx-RuNOisn à luz (&lambda;irr = 355 nm) levou à liberação de NO e provavelmente à formação do fotoproduto trans [RuIII(NH3)4isn(H2O)]3+ no filme. A reação desse aquocomplexo de rutênio(III) com solução aquosa contendo nitrito de sódio regenerou o complexo de partida, RuNOisn. A identificação e quantificação do NO liberado durante a fotólise foi efetuada por meio da reação com oximioglobina. Durante o tempo de irradiação de 17 minutos, foram liberados 5,02 &plusmn; 0,12 &mu;M de NO (10, 04 &plusmn; 0,24 nmol NO em 2 mL). Os ensaios de liberação de NO desencadeada por redução foram realizados utilizando-se L-cisteína como redutor. O fluxo de NO liberado a partir da reação com cisteína perdurou por mais de 7 horas, alcançando-se concentrações fisiologicamente relevantes, com fluxo médio de 1,9 pmol NO s-1 cm-2 de filme. Esse valor é comparável àquele produzido por células endoteliais, em que o fluxo de NO é de 1,67 pmol s-1 cm-2. Os resultados preliminares de degradação dos filmes in vivo sugerem que o material foi degradado pelo organismo em 30 dias. Todos os resultados alcançados sugerem que o filme CSx-RuNOisn é um candidato promissor para aplicações em meio biológico. Um novo complexo de rutênio contendo o ligante nitrosilsulfito (N(O)SO3 -) foi isolado, trans [Ru(NH3)4(isn)(N(O)SO3)](X) (isn = isonicotinamida, X = PF6- ou SiPF6 2-), e a sua estrutura cristalina determinada por difração de raio-X. A síntese desse complexo foi realizada por meio da reação entre trans-[Ru(NH3)4(isn)(NO)]3+ e íons sulfito (SO32-). O ataque nucleofílico do SO32- ocorreu no nitrogênio do ligante nitrosônio (NO) coordenado ao centro metálico de rutênio ([Ru-NO+]), originando o ligante O=N-SO3-: [RuNO+]3+ + SO32- &rarr;[Ru(N(O)SO3)]+. Observou-se que em meio aquoso, no intervalo de pH de 7,4 a 5,2 o complexo trans [Ru(NH3)4(isn)(N(O)SO3)]+ é estável, e a velocidade de decomposição (labilização do ligante isn) variou de k = 0,86 a 3,07 × 10-5 s-1. Em soluções mais ácidas (tampão ácido acético/acetato pH 4,2, 3,9, ou 1,0 M ácido trifluoroacético) o complexo trans-[Ru(NH3)4(isn)(N(O)SO3)]+ decompõe-se formando o respectivo nitrosilo complexo trans- [RuII(NH3)4(isn)NO+]3+. A reação do íon trans-[Ru(NH3)4(isn)(N(O)SO3)]+ com íons hidróxido (OH-) dá origem ao respectivo nitro complexo trans-[Ru(NH3)4(isn)(NO2)]+, que foi caracterizado por RMN de 15N e por espectroscopia eletrônica. As constantes de velocidade para essa reação são k = 6,16 &plusmn; 0,22 M-1 s-1 à T = 25oC, e k = 2,15 &plusmn; 0,07 M-1 s-1 à T = 15oC. A reação entre o nitrosilo complexo trans [RuII(NH3)4(isn)NO+]3+ e íons OH- também resulta na formação do nitro complexo trans-[Ru(NH3)4(isn)(NO2)]+. Neste caso, a constante de velocidade foi estimada entre k = 47-58 M-1 s-1 à T = 25oC, e o valor obtido experimentalmente à T = 15oC foi de k = 10,53 &plusmn; 0,29 M-1 s-1. O espectro eletrônico do íon complexo trans [Ru(NH3)4(isn)(N(O)SO3)]+ em meio aquoso apresentou uma banda larga com &lambda; max = 362 nm (&epsilon; &sim;6000 M-1 cm-1), atribuída por cálculos teóricos às seguintes transições: transferência de carga do metal para o ligante (TCML) Ru &rarr; N(O)SO3 e Ru &rarr; isn, e também d &rarr; d. Os ensaios preliminares de fotólise (&lambda; irrad = 355 nm) do complexo trans[Ru(NH3)4(isn)(N(O)SO3)](PF6) em solução de tampão fosfato (pH 7,4) sugerem a formação das seguintes espécies nos intervalos iniciais de fotólise: i) NO, ii) SO3 &bull;-, e iii) isn (labilizado do complexo). O mecanismo para a formação desses produtos ainda está sob investigação. / Aiming the production of new nitric oxide releasing materials (NORM), this work reports the development of a cassava starch based film, in which a ruthenium nitrosyl complex was impregnated, and evaluate the NO release from this film. Ruthenium nitrosyl complex trans-[Ru(NH3)4(isn)NO](BF4)3 (RuNOisn; isn = isonicotinamide) is able to release NO in a controlled manner through both photolysis (&lambda;irr = 310-370 nm) and chemical reduction. The incorporation of such complex into the starch-based films was performed under mild conditions, yielding a new material able to store and release NO, abbreviated as CSx-RuNOisn. Spectroscopic analysis of CSx-RuNOisn indicated that the coordination sphere of RuNOisn remained intact during film production. Exposure of CSx-RuNOisn to long wave UV-light (&lambda;irr = 355 nm) leads to NO release and likely to the formation of the paramagnetic photoproduct trans-[RuIII(NH3)4isn(H2O)]3+ in the film. Reaction of this aquoruthenium(III) complex with aqueous nitrite regenerates RuNOisn in the film. Delivery of NO upon photolysis of CSx-RuNO isn was verified and quantified by trapping with oxymyoglobin. The calculated concentration of NO released from the film was 5.02 &plusmn; 0.12 &mu;M (10.04 &plusmn; 0.24 nmol NO in a 2 mL) after approximately 17 min of irradiation (500 laser pulses at 2 s intervals). Moreover, NO release upon chemical reduction was carried out using L-cysteine as a reductant. Cysteine-mediated NO delivery from CSx-RuNOisn persisted for more than 7 h, during which physiologically relevant NO concentrations were liberated (average flux of 1.9 pmol NO s-1 cm-2 of film). This value is comparable to that produced by endothelial cells (1.67 pmol s-1 cm-2). Preliminary results about the biodegradation of the films in vivo suggest that the films were completely absorbed by the organism in a period of 30 days. These results suggest that CSx-RuNOisn is a promising candidate for use in biological applications. A new nitrosylsulphito complex bearing the ligand (N(O)SO3-) was isolated, trans-[Ru(NH3)4(isn)(N(O)SO3)](X) (isn = isonicotinamide, X = PF6- or SiPF6-), and its structure was determined by X-Ray crystallography. This complex was obtained by the reaction between trans-[Ru(NH3)4(isn)(NO)]3+ and sulfite ions (SO32-). X-Ray results confirmed that the nucleophilic attack of the sulphite anion (SO32-) was on the nitrogen atom of the nitrosyl ligand (NO) coordinated to the ruthenium center ([Ru-NO+]), yielding the ligand O=N-SO3-: [RuNO+]3+ + SO32- &rarr; [Ru(N(O)SO3)]+. Complex trans- [Ru(NH3)4(isn)(N(O)SO3)]+ is stable in aqueous solution from pH 7.4 to 5.2, and the decomposition rates (k) (due to the isn labilization) are in the range of k = 0.86-3.07 × 10-5 s-1. In more acidic conditions, (acetate buffer pH 4.2, 3.9, and trifluoroacetic acid solution 1.0 M) complex trans-[Ru(NH3)4(isn)(N(O)SO3)]+ is converted into the respective nitrosyl trans-[RuII(NH3)4(isn)NO+]3+. Reaction of trans-[Ru(NH3)4(isn)(N(O)SO3)]+ and hydroxide ions (OH-) yielded the nitro complex trans-[Ru(NH3)4(isn)(NO2)]+, which was characterized by 15N NMR and electronic spectroscopy. Rate constants for such reaction are k = 6.16 &plusmn; 0.22 M-1 s-1 at 25oC, and k = 2.15 &plusmn; 0.07 M-1 s-1 at 15oC. In the case of complex trans-[RuII(NH3)4(isn)NO+]3+, its reaction with OH- also yield the nitro complex trans-[Ru(NH3)4(isn)(NO2)]+. The estimated rate constant for such reaction was k = 46.9-57.6 M-1 s-1 at 25oC, and the experimental value obtained at 15oC was k = 10.53 &plusmn; 0.29 M-1 s-1. The ion complex trans-[Ru(NH3)4(isn)(N(O)SO3)]+ showed an intense and broad band at 362 nm (&epsilon;&sim;6000 M-1 cm-1) in aqueous solutions, which was assigned by DFT calculations to the following transitions: metal to ligand charge transfer (MLCT) Ru&rarr;N(O)SO3 and Ru&rarr;isn, and d&rarr;d as well. Preliminary photolysis assays (&lambda;irrad = 355 nm) performed with complex trans-[Ru(NH3)4(isn)(N(O)SO3)](PF6) in phosphate buffer solution (pH 7,4) suggests that the following species have been formed (in the initial photolysis period): i) NO, ii) SO3&bull;-, and iii) isn (labilized). The whole mechanism to yield such products is still under investigation.

<p>The gastrointestinal mucus gel layer and blood flow are two important mechanisms for protection at the pre-epithelial and sub-epithelial levels, respectively. <i>Helicobacter pylori</i> might circumvent these mechanisms and elicit a chronic inflammatory response with consequent ulcers in the stomach and duodenum. In this thesis, the physical state and properties of the adherent mucus gel layer was studied from the stomach to colon. Furthermore, the acute and chronic effects of <i>H. pylori</i> on the integrity of the mucus gel layer and mucosal blood flow were studied in the anesthetized rat.</p><p>A translucent mucus gel covers all studied segments of the gastrointestinal tract during fasting conditions, with the thickest layers in the colon and ileum. Carefully applied suction revealed that the mucus gel was a multi-layered structure comprising a firmly adherent layer covering the mucosa, impossible to remove, and a loosely adherent upper layer. The firmly adherent layer was thick and continuous in the corpus (80μm), antrum (154μm) and colon (116μm), but thin (<20μm) and discontinuous in the small intestine.</p><p>Following mucus removal, a rapid renewal of the loosely adherent layer ensued. The highest rate was observed in the colon with intermediate values in the small intestine. Mucus renewal in the stomach was attenuated on acute luminal application of water extracts from <i>H. pylori</i> (HPE). In animals with a chronic <i>H. pylori</i> infection the mucus renewal rate was unaffected, but the total gastric mucus gel thickness was reduced and the mucus secretory response to luminal acid (pH1) attenuated in the antrum. </p><p>HPE from type I strains acutely reduced corporal mucosal blood flow, measured with laser-Doppler flowmetry, by approximately 15%. The reduction in blood flow was mediated by a heat stable factor other than VacA and CagA. Inhibition of endogenous nitric oxide production with Nω-nitro-l-arginine augmented the decrease. However, ketotifen, a mast cell stabilizer, completely attenuated the effect of the extract as did the platelet activating factor (PAF) receptor-antagonist, WEB2086, thus depicting a detrimental role for the microvascular actions of PAF.</p>

The gastrointestinal mucus gel layer and blood flow are two important mechanisms for protection at the pre-epithelial and sub-epithelial levels, respectively. Helicobacter pylori might circumvent these mechanisms and elicit a chronic inflammatory response with consequent ulcers in the stomach and duodenum. In this thesis, the physical state and properties of the adherent mucus gel layer was studied from the stomach to colon. Furthermore, the acute and chronic effects of H. pylori on the integrity of the mucus gel layer and mucosal blood flow were studied in the anesthetized rat. A translucent mucus gel covers all studied segments of the gastrointestinal tract during fasting conditions, with the thickest layers in the colon and ileum. Carefully applied suction revealed that the mucus gel was a multi-layered structure comprising a firmly adherent layer covering the mucosa, impossible to remove, and a loosely adherent upper layer. The firmly adherent layer was thick and continuous in the corpus (80μm), antrum (154μm) and colon (116μm), but thin (&lt;20μm) and discontinuous in the small intestine. Following mucus removal, a rapid renewal of the loosely adherent layer ensued. The highest rate was observed in the colon with intermediate values in the small intestine. Mucus renewal in the stomach was attenuated on acute luminal application of water extracts from H. pylori (HPE). In animals with a chronic H. pylori infection the mucus renewal rate was unaffected, but the total gastric mucus gel thickness was reduced and the mucus secretory response to luminal acid (pH1) attenuated in the antrum. HPE from type I strains acutely reduced corporal mucosal blood flow, measured with laser-Doppler flowmetry, by approximately 15%. The reduction in blood flow was mediated by a heat stable factor other than VacA and CagA. Inhibition of endogenous nitric oxide production with Nω-nitro-l-arginine augmented the decrease. However, ketotifen, a mast cell stabilizer, completely attenuated the effect of the extract as did the platelet activating factor (PAF) receptor-antagonist, WEB2086, thus depicting a detrimental role for the microvascular actions of PAF.

The aim of the study was to examine the immune response and different immunoprotective strategies in experimental type 1 diabetes mellitus. The autoimmune destruction of the insulin-producing pancreatic β-cells that leads to type 1 diabetes is complex and incompletely understood. Activated immune cells infiltrate the pancreatic islets at an early stage of the disease, and they produce and release cytokines, which may contribute to β-cell dysfunction and death. Several immunomodulatory agents with different mechanisms have recently been developed in order to suppress cytokine function such as MDL 201, 449A, a novel transcriptional inhibitor of TNF-α. At least in rodent β-cells, many of the toxic actions of cytokines depend on the synthesis of nitric oxide (NO). Aminoguanidine (AG), an inhibitor of NO formation, might therefore be an interesting compound for prevention of type 1 diabetes. Another substance that could influence the course of events leading to this disease is the pituitary hormone prolactin (PRL), since it has the ability to activate different immune cells. We have studied the effects of AG, PRL and MDL 201, 449A on the development of hyperglycaemia and pancreatic insulitis in multiple low dose streptozotocin induced autoimmune diabetes in mice. The natural course after syngeneic islet transplantation of pancreatic islets in NOD mice, a model of type 1 diabetes mellitus was also investigated. AG and PRL were also studied in vitro on cultured isolated rodent pancreatic islets. We suggest that the insulin-producing cells are specifically targeted by the inflammatory response after syngeneic islet transplantation in type 1 diabetic mice. Our data do not exclude a role for NO in type 1 diabetes, but it raises concerns about the use of AG as a therapeutic agent since an increased mortality and no decline in diabetes frequency was observed. AG did not seem to be directly harmful to β-cell function, but it could affect pancreatic and islet blood flows. PRL and MDL 201, 449A could both counteract hyperglycaemia and insulitis in the early phase of autoimmune diabetes.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 5 uppsatser.

Η εξέλιξη της χρόνιας νεφρικής νόσου χαρακτηρίζεται από προοδευτική απώλεια της νεφρικής λειτουργίας και εναπόθεση εξωκυττάριας ύλης που οδηγεί σε γενικευμένη ίνωση του νεφρικού ιστού. Στους μηχανισμούς που ενοχοποιούνται για την εξέλιξη της βλάβης αυτής προς ίνωση συμμετέχουν κυτταροκίνες και αυξητικοί παράγοντες που προέρχονται από ενδοθηλιακά, επιθηλιακά σωληναριακά κύτταρα και κύτταρα του διάμεσου νεφρικού ιστού. Η ίνωση του διάμεσου νεφρικού χώρου είναι μία κοινή διαδικασία που χαρακτηρίζεται από την de novo ενεργοποίηση μυοϊνοβλαστών με αποτέλεσμα την αυξημένη εναπόθεση εξωκυττάριας ύλης. Τα επιθηλιακά σωληναριακά κύτταρα είναι πηγή προέλευσης των ενεργοποιημένων μυοϊνοβλαστών μέσω μιας διαδικασίας που ονομάζεται επιθηλιακή προς μεσεγχυματική μετάπτωση. Διάφοροι μεσολαβητές της νεφρικής βλάβης όπως είναι και η κυκλοσπορίνη ερχόμενοι σε επαφή με κύτταρα του εγγύς εσπειραμένου σωληναρίου οδηγούν σε ενεργοποίηση προϊνωτικών παραγόντων εκκρίνοντας εξωκυττάρια ύλη. Μεταξύ αυτών των μεσολαβητών της νεφρικής βλάβης, ιδιαίτερο ρόλο φαίνεται ότι διαδραματίζουν το νιτρικό οξείδιο και η ενδοθηλίνη, δύο παράγοντες που μετέχουν σε φυσιολογικές, αλλά και παθοφυσιολογικές κυτταρικές διαδικασίες. Τα συστήματα νιτρικού οξειδίου και ενδοθηλίνης αλληλεπιδρούν μεταξύ τους σε επίπεδο υποδοχέων στο κυτταρικό επίπεδο προκαλώντας αλλαγές του αγγειακού τόνου και ενεργοποίηση ή αναστολή προϊνωτικών σημάτων. Ο σκοπός της εργασίας ήταν η μελέτη της έκφρασης των συστημάτων νιτρικού οξειδίου και ενδοθηλίνης σε σωληναριακά νεφρικά κύτταρα κάτω από την επίδραση της κυκλοσπορίνης. Χρησιμοποιήθηκαν ανθρώπινες κυτταροκαλλιέργειες νεφρικών επιθηλιακών κυττάρων του εγγύς εσπειραμένου σωληναρίου (ΗΚ-2) τα οποία επωάσθηκαν σε θεραπευτικές και τοξικές συγκεντρώσεις κυκλοσπορίνης (CsA) και ακολούθησε η ανίχνευση του νιτρικού οξειδίου (NO), της ενδοθηλιακής και επαγώγιμης συνθετάσης του ΝΟ (e-NOS, i-NOS) και της ενδοθηλίνης-1 (ET-1) με τους Α και Β υποδοχείς της (ΕΤ-Α, ΕΤ-Β). Το ΝΟ μετρήθηκε σύμφωνα με τη μέθοδο Griess, ενώ η συσσώρευση της ενδοθηλίνης και των Α και Β υποδοχέων της καθώς και οι συνθετάσες του ΝΟ ανιχνεύθηκαν τόσο σε επίπεδο μεταγράφου (m-RNA) χρησιμοποιώντας RT-PCR, όσο και σε επίπεδο πρωτεΐνης με Western Blot ανάλυση. Πειράματα πραγματοποιήθηκαν επίσης χρησιμοποιώντας ταυτόχρονα στο επωαστικό μέσο εκτός από κυκλοσπορίνη και ειδικούς αναστολείς του ΝΟ (L-NAME) και των υποδοχέων της ενδοθηλίνης (BQ123, BQ 788), ενώ ακολούθησε η ανίχνευση των συνθετασών του ΝΟ και των υποδοχέων της ενδοθηλίνης αντίστοιχα. Από τα πειράματα που πραγματοποιήθηκαν προκύπτει ότι η κυκλοσπορίνη ασκεί τοξική δράση σε νεφρικά σωληναριακά κύτταρα και επάγει τη συσσώρευση της ΕΤ-1,του ΝΟ, των συνθετασών του ΝΟ και των Α και Β υποδοχέων της ΕΤ-1. Η επαγωγή του ΕΤ-Α υποδοχέα είναι ανεξάρτητη από την παρουσία ή μη ΝΟ, σε αντίθεση με τον ΕΤ-Β υποδοχέα η επαγωγή του οποίου καταστέλλεται πλήρως όταν αναστέλλεται το σύστημα του νιτρικού οξειδίου (L-NAME). Η επαγωγή της e-NOS από την κυκλοσπορίνη είναι απόλυτα εξαρτώμενη από το σύστημα της ΕΤ-1, σε αντίθεση με την i-NOS η οποία επάγεται σε σημαντικό βαθμό ακόμη και όταν το σύστημα ενδοθηλίνης αδρανοποιείται πλήρως με ειδικούς αναστολείς (BQ123 και BQ788). / The progression of renal fibrosis is characterized by loss of kidney function and deposition of extracellular matrix components. The mechanism implicated in the development of renal fibrosis involves cytokines and growth factors originating from endothelial, tubular epithelial and interstitial cells. Activated myofibloblasts derive from differentiated tubular epithelial cells trough a process called epithelial to mesenchymal transition. Various kidney injury mediators like cyclosporine-A (CsA) are entering the luminal space of the tubules causing activation of profibrotic factors such as nitric oxide (NO) and endothelin-1 (ET-1). A cross talk exists between endothelin and NO systems in the regulation of vascular tone and inflammatory process. Aim of this study was to investigate the effect of cyclosporine-A on the expression of Nitric Oxide and endothelin-1 on cultured renal tubular cells. Human tubular epithelial cells (HK-2) were cultured in the presence of CsA at various concentrations (0 -1,000 ng/ml). RT-PCR was used to determine NO synthases (eNOS, iNOS) and endothelin receptors (ETR-A, ETR-B) and Western Blot analysis for the subsequent proteins. Similar experiments were also carried out using specific NO (L-NAME) and endothelin receptor (BQ123, BQ 788) inhibitors. At therapeutic concentrations, CsA exerts a significant cytotoxic effect on tubular epithelial cells. A dose dependent activation of NO synthases eNOS and iNOS and endothelin receptors ET-A and ETR-B was observed, even at therapeutic concentrations of CsA. An interaction between NO and ET-1 systems under the influence of CsA was also observed, since blockage of NO production was followed by down-regulation of ET-B while blocking of endothelin pathway with ET receptor antagonists, was followed by down-regulation of eNOS expression.